Related references
Note: Only part of the references are listed.Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Daniel V. T. Catenacci et al.
CANCER DISCOVERY (2021)
Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
Emina Torlakovic et al.
MODERN PATHOLOGY (2020)
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Ronan J. Kelly et al.
CLINICAL CANCER RESEARCH (2020)
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
M. Moehler et al.
ANNALS OF ONCOLOGY (2020)
Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).
Markus H. Moehler et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma
Ayesha Noorani et al.
NATURE GENETICS (2020)
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
Jacob J. Adashek et al.
ONCOLOGIST (2020)
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis
Jianchun Duan et al.
JAMA ONCOLOGY (2020)
Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas
S. Derks et al.
ANNALS OF ONCOLOGY (2020)
Circulating tumor DNA (ctDNA) dynamics associate with treatment response and radiological progression-free survival (rPFS): Analyses from a randomized phase II trial in metastatic castration-resistant prostate cancer (mCRPC).
Jane Goodall et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
Yelena Y. Janjigian et al.
LANCET ONCOLOGY (2020)
The Cancer-Immune Set Point in Oesophageal Cancer
Robert Power et al.
FRONTIERS IN ONCOLOGY (2020)
Critical role of eosinophils during response to immune checkpoint blockade in breast cancer and other cancer types
L. Voorwerk et al.
ANNALS OF ONCOLOGY (2020)
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial
Daniel V. T. Catenacci et al.
LANCET ONCOLOGY (2020)
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer
Yuki Kiyozumi et al.
ANNALS OF SURGERY (2019)
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities
Yada Kanjanapan et al.
CANCER (2019)
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Giuseppe Lo Russo et al.
CLINICAL CANCER RESEARCH (2019)
Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
Richard C. Turkington et al.
GUT (2019)
The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic
Alexander M. Frankell et al.
NATURE GENETICS (2019)
Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naive Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival
Maria C. Svensson et al.
FRONTIERS IN ONCOLOGY (2019)
Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer
Taisuke Yagi et al.
EUROPEAN JOURNAL OF CANCER (2019)
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Debarati Banik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications
Yuxin Lin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
T Cell Dysfunction in Cancer Immunity and Immunotherapy
Anliang Xia et al.
FRONTIERS IN IMMUNOLOGY (2019)
Role of Cancer-Associated Fibroblast in Gastric Cancer Progression and Resistance to Treatments
In-Hye Ham et al.
JOURNAL OF ONCOLOGY (2019)
Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
Steven B. Maron et al.
CLINICAL CANCER RESEARCH (2019)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato et al.
LANCET ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment
Xin Li et al.
FRONTIERS IN IMMUNOLOGY (2019)
The immune landscape of esophageal cancer
Tu-Xiong Huang et al.
CANCER COMMUNICATIONS (2019)
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Jason J. Luke et al.
CLINICAL CANCER RESEARCH (2019)
The Interferon-Gamma Paradox in Cancer
M. Raza Zaidi
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2019)
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
Eirini Pectasides et al.
CANCER DISCOVERY (2018)
Cancer-Associated Fibroblasts Affect Intratumoral CD8+ and FoxP3+ T Cells Via IL6 in the Tumor Microenvironment
Takuya Kato et al.
CLINICAL CANCER RESEARCH (2018)
Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma
Elizabeth C. Smyth et al.
LANCET (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Myeloid-derived suppressor cells coming of age
Filippo Veglia et al.
NATURE IMMUNOLOGY (2018)
Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab
Asuncion Diaz-Serrano et al.
ONCOLOGIST (2018)
Targeting veGF/veGFR to Modulate Antitumor immunity
Ju Yang et al.
FRONTIERS IN IMMUNOLOGY (2018)
Alteration of the Antitumor immune Response by Cancer-Associated Fibroblasts
Linda Ziani et al.
FRONTIERS IN IMMUNOLOGY (2018)
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Rebekka Weber et al.
FRONTIERS IN IMMUNOLOGY (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y. -J. Bang et al.
ANNALS OF ONCOLOGY (2018)
Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC).
Youjin Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Yelena Y. Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
Jonathan A. Trujillo et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara et al.
JAMA ONCOLOGY (2018)
210TiPIMbrave150: A randomised phase III study of atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma
S Qin et al.
ANNALS OF ONCOLOGY (2018)
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Stephane Champiat et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer
Kousaku Mimura et al.
CANCER SCIENCE (2018)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Detecting particles of dark matter
Jihn E. Kim et al.
NATURE (2017)
Integrated genomic characterization of oesophageal carcinoma
Jihun Kim et al.
NATURE (2017)
Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature
Xixi Zhao et al.
ONCOTARGET (2017)
Reciprocal Expression of IL-35 and IL-10 Defines Two Distinct Effector Treg Subsets that Are Required for Maintenance of Immune Tolerance
Xundong Wei et al.
CELL REPORTS (2017)
Oesophageal cancer
Elizabeth C. Smyth et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer
Yung-Jue Bang et al.
CLINICAL CANCER RESEARCH (2017)
Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project
Bo Hwa Sohn et al.
CLINICAL CANCER RESEARCH (2017)
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2017)
Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor
Rajeev Dhupar et al.
ANNALS OF THORACIC SURGERY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
High Infiltration of Tumor-Associated Macrophages Influences Poor Prognosis in Human Gastric Cancer Patients, Associates With the Phenomenon of EMT
Jia Zhang et al.
MEDICINE (2016)
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
Maria Secrier et al.
NATURE GENETICS (2016)
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Vinit Kumar et al.
TRENDS IN IMMUNOLOGY (2016)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen et al.
CANCER DISCOVERY (2016)
PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
Christine Boeger et al.
ONCOTARGET (2016)
Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges
Feifei Teng et al.
CANCER LETTERS (2015)
VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation
Hua Huang et al.
FASEB JOURNAL (2015)
Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma
Timothy J. Underwood et al.
JOURNAL OF PATHOLOGY (2015)
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
Rosa Barreira da Silva et al.
NATURE IMMUNOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Second-line treatment of metastatic gastric cancer: Current options and future directions
Dheepak Kanagavel et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy
Erika Vacchelli et al.
ONCOTARGET (2015)
Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells
Dachun Wang et al.
STEM CELLS TRANSLATIONAL MEDICINE (2015)
Breaching the castle walls: hyaluronan depletion as a therapeutic approach to cancer therapy
H. Michael Shepard
FRONTIERS IN ONCOLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
Emerging roles of regulatory T cells in tumour progression and metastasis
Elizabeth C. Halvorsen et al.
CANCER AND METASTASIS REVIEWS (2014)
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Christiane Meyer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Adverse Immunoregulatory Effects of 5FU and CPT11 Chemotherapy on Myeloid-Derived Suppressor Cells and Colorectal Cancer Outcomes
Julia Kanterman et al.
CANCER RESEARCH (2014)
Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
Antje Sucker et al.
CLINICAL CANCER RESEARCH (2014)
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
Susan J. Dutton et al.
LANCET ONCOLOGY (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
A global assessment of the oesophageal adenocarcinoma epidemic
Gustaf Edgren et al.
GUT (2013)
Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome
Marcus Bettstetter et al.
HUMAN PATHOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy
Chao Ma et al.
CANCER DISCOVERY (2013)
Involvement of CXCR4 Chemokine Receptor in Metastastic HER2-Positive Esophageal Cancer
Stephanie J. Gros et al.
PLOS ONE (2012)
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
Rachel F. Gabitass et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
Claus Garbe et al.
ONCOLOGIST (2011)
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
Thomas Condamine et al.
TRENDS IN IMMUNOLOGY (2011)
Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy
Luca Gattinoni et al.
CLINICAL CANCER RESEARCH (2010)
Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
Christy Ralph et al.
CLINICAL CANCER RESEARCH (2010)
The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma
Richard Keld et al.
MOLECULAR CANCER (2010)
Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases
Jane Hoyt Buckner
NATURE REVIEWS IMMUNOLOGY (2010)
The Erk2 MAPK Regulates CD8 T Cell Proliferation and Survival
Warren N. D'Souza et al.
JOURNAL OF IMMUNOLOGY (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers
Bo Huang et al.
CANCER LETTERS (2007)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
Mechanisms of type-I- and type-II-interferon-mediated signalling
LC Platanias
NATURE REVIEWS IMMUNOLOGY (2005)
Share Paper
